Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Msd R&d Co., Ltd.

Helen J Mitchell

Mark E Fraley

Robert S Meissner

Daniel Vincent Paone

Cheng Wang

Steven N Gallicchio

Donnette D Staas

C Blair Zartman

Anthony T Ginnetti

William P Dankulich

James J Perkins

Chun Sing Li

Qinghua Mao

Yuntae Kim

Craig A Stump

Casey Cameron McComas

Ping Liu

Andrew John Cooke

Barbara Hanney

Swati P Mercer

Scott D Kuduk

Tesfaye Biftu

Yi Heng Chen

Ian M Bell

Harold B Wood

Jiabing Wang

Melody McWherter

Yi-Heng Chen

Jianming Bao

Deping Wang

Douglas C Beshore

Philippe G Nantermet

Cheng Zhu

Dongfang Meng

Kerim Babaoglu

Anilkumar G Nair

Deyou Sha

Keith P Moore

Antonella Converso

Mildred L Kaufman

Xu-Fang Zhang

Kathy Schirripa

Heather E Stevenson

Michael R Krout

Jeffrey Musselman

Zhiqi Qi

Danielle M McMaster

Dann Parker

Ashley Forster

Jane Yang Wu

David N Hunter

Abdellatif El Marrouni

Blair C Zartman

William P Danulich

Anthony Ginetti

Andrew J Cooke

Melody Mcwherter

William Daniel Shipe

Steven N Gallicho

Chang Wang

Casey C Mccomas

Anthony Ginnetti

Danielle M Mcmaster

Jeffrey D Musselman

Jessica L Frie

Philippe Nantermet

Daniel V Paone

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide azaindane CGRP receptor antagonists

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TrKA kinase inhibitors, compositions and methods thereof

The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TRKA kinase inhibitors, compositions and methods thereof

TrkA kinase inhibitors, compositions and methods thereof

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide indane CGRP receptor antagonists

The present invention is directed to aliphatic spirolactam derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Aliphatic spirolactam CGRP receptor antagonists

The present invention is directed to hexahydrocyclopentylf]imidazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

[object Object]

The present invention is directed to hexahydrocyclopentylf]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators

Growing community of inventors

Richboro, PA, United States of America

Helen J Mitchell